Agios Pharmaceuticals (AGIO) closed at $31.38 on November 9, 2026, up 6.7% from the previous close, on volume of 1,108,826 shares (30-day average 1,274,285).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Call with Delta Hedge | 20-Nov-26 35 C +29,006 Stock | 821 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty
TipRanks (Sun, 8-Nov 7:25 PM ET)
Bank of America Securities Sticks to Its Buy Rating for Agios Pharma (AGIO)
TipRanks (Fri, 6-Nov 7:59 AM ET)
TipRanks (Thu, 5-Nov 5:40 PM ET)
Agios Pharmaceuticals GAAP EPS of -$1.09 beats by $0.15, revenue of $55.39M beats by $3.79M
Seeking Alpha News (Thu, 5-Nov 6:43 AM ET)
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 5-Nov 6:30 AM ET)
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
Globe Newswire (Fri, 30-Oct 7:00 AM ET)
Globe Newswire (Thu, 8-Oct 7:00 AM ET)
Market Chameleon (Tue, 7-Jul 7:43 AM ET)
Market Chameleon (Tue, 31-Mar 4:13 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of November 9, 2026, AGIO stock price climbed to $31.38 with 1,108,826 million shares trading.
AGIO has a beta of 2.02, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.09 to the broad based SPY ETF.
AGIO has a market cap of $1.87 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $55 million in Revenue and -$1.09 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.16.
In the last 3 years, AGIO traded as high as $62.58 and as low as $20.40.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, XBI, IWM, VB, VBK.
AGIO has underperformed the market in the last year with a price return of -22.8% while the SPY ETF gained +13.3%. AGIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.8% and -14.8%, respectively, while the SPY returned -2.4% and -1.7%, respectively.
AGIO support price is $28.24 and resistance is $30.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.
